Literature DB >> 2795349

Quantitation of urinary carnitine esters in a patient with medium-chain acyl-coenzyme A dehydrogenase deficiency: effect of metabolic state and L-carnitine therapy.

E Schmidt-Sommerfeld1, D Penn, J Kerner, L L Bieber, T M Rossi, E Lebenthal.   

Abstract

Urinary carnitine esters were quantitated in an infant with medium-chain acylcoenzyme A dehydrogenase deficiency by means of a highly sensitive and specific radioisotopic exchange high-pressure liquid chromatography method. During fasting, the excretion of free carnitine and of acetylcarnitine, octanoylcarnitine, and hexanoylcarnitine was increased. The fractional tubular reabsorption of free carnitine was decreased, suggesting a renal leak of free carnitine. In the symptom-free, fed state, only minor amounts of free carnitine and of short-chain acylcarnitine, octanoylcarnitine, and hexanoylcarnitine were present in urine, and carnitine loss occurred in the form of "other" carnitine esters not exceeding that of control subjects. During L-carnitine therapy, the excretion of free carnitine, short-chain acylcarnitine, octanoylcarnitine, and hexanoylcarnitine, and particularly of "other" carnitine esters, was increased, suggesting a possible detoxifying effect of administered carnitine that is not confined to the elimination of octanoic and hexanoic acids. The employed method detects very low urinary concentrations of octanoylcarnitine and hexanoylcarnitine (less than 1 mumol/L) characteristic of medium-chain acyl-coenzyme A dehydrogenase deficiency and may be useful in screening for this disease, which has been associated with sudden infant death.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2795349     DOI: 10.1016/s0022-3476(89)80284-7

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

1.  Postperfusion energy metabolism of steatotic graft and its relation to early graft viability following liver transplantation.

Authors:  C Miki; K Iriyama; D F Mirza; A D Mayer; J A Buckels; H Suzuki; P McMaster
Journal:  Dig Dis Sci       Date:  1998-01       Impact factor: 3.199

Review 2.  L-Carnitine.

Authors:  J H Walter
Journal:  Arch Dis Child       Date:  1996-06       Impact factor: 3.791

Review 3.  L-Carnitine and Acetyl-L-carnitine Roles and Neuroprotection in Developing Brain.

Authors:  Gustavo C Ferreira; Mary C McKenna
Journal:  Neurochem Res       Date:  2017-05-16       Impact factor: 3.996

Review 4.  Acylcarnitines in intermediary metabolism.

Authors:  A C Sewell; H J Böhles
Journal:  Eur J Pediatr       Date:  1995-11       Impact factor: 3.183

Review 5.  Carnitine esters in metabolic disease.

Authors:  H Böhles; A Evangeliou; K Bervoets; I Eckert; A Sewell
Journal:  Eur J Pediatr       Date:  1994       Impact factor: 3.183

6.  Serum hepatocyte growth factor as an index of extensive catabolism of patients awaiting liver transplantation.

Authors:  C Miki; A D Mayer; J A Buckels; K Iriyama; H Suzuki; P McMaster
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

Review 7.  Medium-chain acyl-CoA dehydrogenase deficiency: molecular aspects.

Authors:  Y Matsubara; K Narisawa; K Tada
Journal:  Eur J Pediatr       Date:  1992-03       Impact factor: 3.183

8.  L-carnitine in inborn errors of metabolism: what is the evidence?

Authors:  J H Walter
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

Review 9.  Medium chain acyl-CoA dehydrogenase deficiency.

Authors:  E H Touma; C Charpentier
Journal:  Arch Dis Child       Date:  1992-01       Impact factor: 3.791

Review 10.  Establishing core outcome sets for phenylketonuria (PKU) and medium-chain Acyl-CoA dehydrogenase (MCAD) deficiency in children: study protocol for systematic reviews and Delphi surveys.

Authors:  Beth K Potter; Brian Hutton; Tammy J Clifford; Nicole Pallone; Maureen Smith; Sylvia Stockler; Pranesh Chakraborty; Pauline Barbeau; Chantelle M Garritty; Michael Pugliese; Alvi Rahman; Becky Skidmore; Laure Tessier; Kylie Tingley; Doug Coyle; Cheryl R Greenberg; Lawrence Korngut; Alex MacKenzie; John J Mitchell; Stuart Nicholls; Martin Offringa; Andreas Schulze; Monica Taljaard
Journal:  Trials       Date:  2017-12-19       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.